MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558075 | Name: Bismuth subsalicylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate. It is used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach.

Chemical Structure

Bismuth subsalicylate
Bismuth subsalicylate
CAS#14882-18-9

Theoretical Analysis

MedKoo Cat#: 558075

Name: Bismuth subsalicylate

CAS#: 14882-18-9

Chemical Formula: C7H5BiO4

Exact Mass: 362.0000

Molecular Weight: 362.09

Elemental Analysis: C, 23.22; H, 1.39; Bi, 57.71; O, 17.67

Price and Availability

Size Price Availability Quantity
25g USD 250.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Bismuth oxide salicylate; Bismuth subsalicylate;
IUPAC/Chemical Name
4H-1,3,2-Benzodioxabismin-4-one, 2-hydroxy-
InChi Key
ZREIPSZUJIFJNP-UHFFFAOYSA-K
InChi Code
InChI=1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3
SMILES Code
O=C1O[Bi](O)OC2=CC=CC=C12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 362.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pitz AM, Park GW, Lee D, Boissy YL, Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93-100. doi: 10.1080/19490976.2015.1008336. PubMed PMID: 25901890; PubMed Central PMCID: PMC4615802. 2: Hinostroza Morales D, Díaz Ferrer J. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]. Rev Gastroenterol Peru. 2014 Oct-Dec;34(4):315-20. Spanish. PubMed PMID: 25594755. 3: Sheele J, Cartowski J, Dart A, Poddar A, Gupta S, Stashko E, Ravi BS, Nelson C, Gupta A. Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera. Pathog Glob Health. 2015 Sep;109(6):275-82. doi: 10.1179/2047773215Y.0000000028. Epub 2015 Aug 11. PubMed PMID: 26260354; PubMed Central PMCID: PMC4727582. 4: Bingham AL, Brown RO, Dickerson RN. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. Nutr Clin Pract. 2013 Dec;28(6):766-9. doi: 10.1177/0884533613507606. Epub 2013 Oct 25. PubMed PMID: 24163322. 5: Abed J, Mankal P, Judeh H, Kim S. Acute Esophageal Necrosis: A Case of Black Esophagus Associated with Bismuth Subsalicylate Ingestion. ACG Case Rep J. 2014 Apr 4;1(3):131-3. doi: 10.14309/crj.2014.27. eCollection 2014 Apr. PubMed PMID: 26157851; PubMed Central PMCID: PMC4435298. 6: Ruiz-Moreno M, Binversie E, Fessenden SW, Stern MD. Mitigation of in vitro hydrogen sulfide production using bismuth subsalicylate with and without monensin in beef feedlot diets. J Anim Sci. 2015 Nov;93(11):5346-54. doi: 10.2527/jas.2015-9392. PubMed PMID: 26641054. 7: Yakoob J, Abbas Z, Usman MW, Awan S, Naz S, Jafri F, Hamid S, Jafri W. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. Microb Drug Resist. 2014 Aug;20(4):305-9. doi: 10.1089/mdr.2013.0086. Epub 2013 Jul 11. PubMed PMID: 23844851. 8: Khara HS, Diehl DL, Metwally MJ, Schwender BJ. Bismuth subsalicylate tablet masquerading as vanishing button battery in the stomach. Gastrointest Endosc. 2014 Mar;79(3):539-40. doi: 10.1016/j.gie.2013.10.012. PubMed PMID: 24528833. 9: Tanaka S, Guth PH, Carryl OR, Kaunitz JD. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration. Aliment Pharmacol Ther. 1997 Jun;11(3):605-12. PubMed PMID: 9218090. 10: Goldman RD. Bismuth salicylate for diarrhea in children. Can Fam Physician. 2013 Aug;59(8):843-4. PubMed PMID: 23946025; PubMed Central PMCID: PMC3743694. 11: Dodge AG, Wackett LP. Metabolism of bismuth subsalicylate and intracellular accumulation of bismuth by Fusarium sp. strain BI. Appl Environ Microbiol. 2005 Feb;71(2):876-82. PubMed PMID: 15691943; PubMed Central PMCID: PMC546758. 12: Tay HP, Chaparala RC, Harmon JW, Huesken J, Saini N, Hakki FZ, Schweitzer EJ. Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits. Gut. 1990 Jan;31(1):11-6. PubMed PMID: 2108076; PubMed Central PMCID: PMC1378333. 13: DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A, Mathewson JJ. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med. 1990 Jun 20;88(6A):15S-19S. PubMed PMID: 2192553. 14: Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA. 1986 Feb 14;255(6):757-60. PubMed PMID: 3944976. 15: Wagner S, Gebel M, Haruma K, Bär W, Lange P, Freise J, Gladziwa U, Schmidt FW. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori. Gut. 1992 Feb;33(2):179-83. PubMed PMID: 1347278; PubMed Central PMCID: PMC1373926. 16: Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983 Nov;85(5):1017-22. PubMed PMID: 6352386. 17: DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont MW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA. 1987 Mar 13;257(10):1347-50. PubMed PMID: 3820443. 18: Suarez FL, Furne JK, Springfield J, Levitt MD. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology. 1998 May;114(5):923-9. PubMed PMID: 9558280. 19: Dy RM, Lof J, DiBaise JK, Quigley EM. Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man. Dig Dis Sci. 1999 Feb;44(2):286-9. PubMed PMID: 10063913. 20: Hailey FJ, Newsom JH. Evaluation of bismuth subsalicylate in relieving symptoms of indigestion. Arch Intern Med. 1984 Feb;144(2):269-72. PubMed PMID: 6365007.

View History

Bisobrin

Bisobrin